This trial is active, not recruiting.

Conditions brain and central nervous system tumors, cognitive/functional effects, long-term effects secondary to cancer therapy in children, psychosocial effects of cancer and its treatment
Treatments cognitive assessment, psychosocial assessment and care, quality-of-life assessment
Phase phase 3
Sponsor Children's Cancer and Leukaemia Group
Start date June 2002
Trial identifier NCT00278239, CCLG-CNS-2002-03, CDR0000454509, EU-20578


RATIONALE: Questionnaires that measure quality of life may improve the ability to plan treatment for patients with primitive neuroectodermal tumors.

PURPOSE: This phase III trial is studying quality of life in patients who have undergone previous treatment for primitive neuroectodermal tumors.

United States No locations recruiting
Other countries No locations recruiting

Primary Outcomes

Quality of life (QOL) as measured by QOL questionnaire
time frame:

Secondary Outcomes

Quality of survival compared among children undergoing different treatments by Health Utilities Index
time frame:

Eligibility Criteria

Male or female participants from 3 years up to 24 years old.

DISEASE CHARACTERISTICS: - Surviving primitive neuroectodermal tumor (PNET) patients previously enrolled in International Pediatric Oncology Society (SIOP) 2 or 3 phase III treatment trials - Surviving PNET patients eligible for and treated according to PNET 3 protocol but not randomized - No metastatic disease at time of allocation to treatment - No current progressive disease PATIENT CHARACTERISTICS: - No patient deemed unsuitable for this study by treating clinician PRIOR CONCURRENT THERAPY: - Not specified

Additional Information

Official title Study of Outcome of Children Previously Enrolled in European Trials of Treatment for Primitive Neuroectodermal Tumour (PNET)
Description OBJECTIVES: Primary - Determine the quality of survival of patients in the UK and other European countries enrolled in previous International Society of Pediatric Oncology (SIOP) 2 or 3 phase III trials for treatment of pediatric primitive neuroectodermal tumors (PNET). - Compare the quality of survival between children allocated to different treatments in these trials. Secondary - Determine the framework that will allow similar information to be collected across all participating countries in the PNET 4 trial that opened in autumn 2002. OUTLINE: This is a cross-sectional, multicenter study. Pediatric oncologists, teachers, patients ≥ 12 years old, and parents of children age 3-11 years old complete six questionnaires to assess the patients' motor and sensory function, cognition, behavior, emotion, educational provision and achievement, social integration, and the subjective experience of the patients and their families. PROJECTED ACCRUAL: A total of 229 patients will be accrued for this study.
Trial information was received from ClinicalTrials.gov and was last updated in September 2013.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).